Enasidenib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Idhifa?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test.[2] It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Idhifa |
Other names | AG-221 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617040 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C19H17F6N7O |
Molar mass | 473.383 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[3]